VanEck Biotech ETF · NASDAQ (us_market)
— · — · —
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-02-05$169.58 RISE2025-05-09$140.05 PEAK2025-08-04$165.18 180d | -17.4% 93d | Missed | Missed | — | — | +17.9% 87d | Missed |
DROP2022-08-15$163.51 RISE2022-09-26$136.76 PEAK2022-12-02$170.13 109d | -16.4% 42d | Missed | Missed | — | — | +24.4% 67d | Missed |
DROP2022-02-09$168.20 RISE2022-06-13$132.48 PEAK2022-08-15$163.51 187d | -21.2% 124d | Missed | Missed | — | — | +23.4% 63d | Missed |
DROP2021-12-31$189.34 RISE2022-05-11$134.84 PEAK2022-08-08$161.47 220d | -28.8% 131d | Missed | Missed | — | — | +19.7% 89d | Missed |
DROP2020-02-21$144.75 RISE2020-03-16$114.53 PEAK2020-05-29$160.91 98d | -20.9% 24d | Missed | Missed | — | — | +40.5% 74d | Missed |
First quarter results point to sharpened sector divergence, separating AI-driven winners from those facing structural and geopolitical headwinds.
US growth stocks underperformed in early 2026 amid AI disruption fears and an unresolved conflict in the Middle East.
Active equity investors Carrie King and Erin Xie address key questions about healthcare stocks. Read more here.
Longevity, the length of human life, is the subject of growing scientific and commercial interest. Click here to read more.
The Trump administrationâs recent cuts at the FDA have put the agencyâs executive capacity under strain, which may lead to medicine shortages and less innovation.
Sector ETF report for BBH
FDA drug approvals are reshaping biotech stocksâtrack key decisions, FDA leadership turmoil, and volatility. Click for a look at the issues surrounding the FDA.
While AI remains the dominant theme in corporate earnings, Morningstar Research's David Sekera says investors should keep in mind that not all tech stocks are created equal. Read more here.
Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic.
AI applications in healthcare have emerged across four key areas: prediction, diagnosis, treatment, and system efficiency. Read more here.
Survey data underscored how the war in the Middle East has already had a material impact on economic growth around the world. Read more here.
After a 50%+ run from lows last April through highs in mid-January, the Biotech group has been trending sideways over the last few months. Read more here.
Natera rises after a Delaware court grants a 30% ongoing royalty in its MRD patent battle with ArcherDx and Invitae.
US launch of Operation Epic Fury against Iran in late February triggered the closure of the Strait of Hormuz, spiking energy prices and driving pressure on both equities and bonds.
The U.S. military campaign against the Iranian theocracy has roiled financial markets. As a result of the incursion, oil prices are surging and are up 90%+ since the beginning of the year.
Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strengthâread the Q1 sector assessment here.
Canadaâs economy has generated no economic growth in five months and no job growth in eight months.
After years of technology dominance, market leadership appears to be shifting; will it last? Click here to read more.
The fourth quarter of 2025 revealed a market increasingly defined by AIâs transformative impact across sectors.
IBB and peers are gaining traction as AI transforms biotech, boosting drug discovery, trials and growth prospects across diversified ETF portfolios.